Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nautilus Biotechnology (NAUT) Non-Current Assets (2020 - 2026)

Nautilus Biotechnology has reported Non-Current Assets over the past 7 years, most recently at $78.9 million for Q1 2026.

  • Quarterly results put Non-Current Assets at $78.9 million for Q1 2026, down 8.3% from a year ago — trailing twelve months through Mar 2026 was $293.2 million (down 29.07% YoY), and the annual figure for FY2025 was $85.1 million, down 22.53%.
  • Non-Current Assets reached $78.9 million in Q1 2026 per NAUT's latest filing, down from $85.1 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $175.4 million in Q1 2023 and bottomed at $57.6 million in Q1 2022.
  • Median Non-Current Assets over the past 5 years was $101.8 million (2024), compared with a mean of $105.7 million.
  • Peak annual rise in Non-Current Assets hit 266.07% in 2022, while the deepest fall reached 61.48% in 2022.
  • Over 5 years, Non-Current Assets stood at $162.8 million in 2022, then fell by 20.95% to $128.7 million in 2023, then dropped by 14.61% to $109.9 million in 2024, then dropped by 22.53% to $85.1 million in 2025, then fell by 7.28% to $78.9 million in 2026.
  • Business Quant data shows Non-Current Assets for NAUT at $78.9 million in Q1 2026, $85.1 million in Q4 2025, and $66.6 million in Q3 2025.